GlassScriptPhysician profile
Mario Littman
NPI 1568400612
$2,202.17
in general payments reported to CMS, 2019-2025
21 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.43 · 2020: $295 · 2021: $17.74 · 2022: $153 · 2023: $106 · 2024: $1,153 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $346.35 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $284.89 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $250.01 | 2024-2025 | Austedo Xr, Austedo Xr |
| Dermavant Sciences, INC. | $230.55 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $153.28 | 2024 | Zoryve |
| Organon LLC | $150.00 | 2025 | Vtama |
| Otsuka America Pharmaceutical, INC. | $126.20 | 2022-2024 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $118.46 | 2021-2023 | |
| Medtronic Vascular, INC. | $89.44 | 2020 | |
| Neurocrine Biosciences, INC. | $88.89 | 2024-2025 | Ingrezza |
| Aimmune Therapeutics, INC. | $68.38 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.90 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $44.62 | 2023-2024 | Xtampza |
| Eisai INC. | $43.06 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.44 | 2024 | Jardiance, Synjardy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.86 | 2025 | |
| Urovant Sciences INC | $19.60 | 2022 | |
| Sumitomo Pharma America, INC. | $17.80 | 2023 | Gemtesa |
| Lilly USA, LLC | $17.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.40 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.03 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Littman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.